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Abstract
The continuous evolution of b-lactamases resulting in bacterial resistance to b-lactam antibiotics is a major concern in
public health, and yet the underlying molecular basis or the pattern of such evolution is largely unknown. We investigated
the mechanics of the substrate fspectrum expansion of the class A b-lactamase using PenA of Burkholderia thailandensis as a
model. By analyzing 516 mutated enzymes that acquired the ceftazidime-hydrolyzing activity, we found twelve positions
with single amino acid substitutions (altogether twenty-nine different substitutions), co-localized at the active-site pocket
area. The ceftazidime MIC (minimum inhibitory concentration) levels and the relative frequency in the occurrence of
substitutions did not correlate well with each other, and the latter appeared be largely influenced by the intrinsic
mutational biases present in bacteria. Simulation studies suggested that all substitutions caused a congruent effect,
expanding the space in a conserved structure called the omega loop, which in turn increased flexibility at the active site. A
second phase of selection, in which the mutants were placed under increased antibiotic pressure, did not result in a second
mutation in the coding region, but a mutation that increased gene expression arose in the promoter. This result suggests
that the twelve amino acid positions and their specific substitutions in PenA may represent a comprehensive repertoire of
the enzyme’s adaptability to a new substrate. These mapped substitutions represent a comprehensive set of general
mechanical paths to substrate spectrum expansion in class A b-lactamases that all share a functional evolutionary
mechanism using common conserved residues.
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Introduction
Enzymatic hydrolysis has been the most common mode of
bacterial resistance to b-lactam variants, as b-lactamases are apt to
expand their substrate spectrum with simple mutations [1,2,3].
Since the identification of the first extended-spectrum b-lacta-
mases (ESBLs) in the 1980s, members of the ESBLs have been
steadily increasing following the release of new man-made drugs
[4,5,6]. Analyses of amino acid substitutions in these enzymes have
enhanced our current understanding of substrate spectrum
expansion in class A b-lactamases [1,4]. However, much of the
molecular basis that underlies the adaptability of these enzymes to
new antibiotics remains to be understood. Even in the most
extensively studied TEM-type ESBLs, only a small number of
amino acid substitutions have been confirmed to have a direct role
in the enzyme’s expanded substrate spectrum: ten amino acid
substitutions against b-lactam antibiotics, six against b-lactamase
inhibitors, and two against both [4].
To profile the adaptability of class A b-lactamases to a new
antibiotic, we conducted a large-scale mutant selection with the
chromosomally encoded PenA from B.thailandensis [7] (BTH_II1450
from B. thailandensis strain E264) to investigate its adaptation to an
oxy-imino-cephalosporin, ceftazidime. B. thailandensis is resistant to
penicillins [8], and therefore is a good system for a substrate
expansionstudyofthiskind.Furthermore,becauseB.thailandensis isa
non-pathogenic soil saprophyte [7], it is unlikely that this bacterium
has been heavily exposed to ceftazidime. We expected that with penA
we would be able to observe fresh mutational responses to the
challenges posed by exposure to the new ceftazidime drug.
Furthermore, penA is a closely related ortholog to genes in the
pathogenic species B. pseudomallei, B. mallei, and the Burkholderia cepacia
complex (Bcc) [9,10,11], and the antibiotic regimen used to treat
infections by these bacteria generally includes ceftazidime [12,13].
B. pseudomallei is the etiological agent of septicemic melioidosis,
which is endemic in Southeast Asia and Northeastern Australia
[14]. B. mallei, the cause of glanders, is a species derived from a
clone of B. pseudomallei [15]. The Bcc, which is a complex
composed of more than 10 Burkholderia species, including B. cepacia,
B. cenocepacia, and B. multivorans, is a group of nosocomial pathogens
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37585of increasing concern as these bacteria cause respiratory and
systemic infections in patients with cystic fibrosis (CF) or chronic
granulomatous disease, and in other immuno-compromised
patients [12]. To date, only a few cases of ceftazidime resistance
in B. pseudomallei and Bcc have been reported and resistance in
most of these cases pointed to a single gene [9,10,11,16]. Two
single amino acid substitutions, Pro167Ser and Cys69Tyr (amino
acid residue numbering following Ambler et al. [17]), have been
described in PenA of ceftazidime resistant B. pseudomallei isolates
[10,11,16]. Similarly, two orthologs of PenA, PenB2 and PenB3,
with 7 and 2 amino acid alterations, respectively, were shown to be
associated with ceftazidime resistance in clinical isolates of B.
cenocepacia [9].
Results and Discussion
All 516 Ceftazidime-resistant Mutants had a Mutation in
the penA Gene
We measured the intrinsic level of the susceptibility of the wild-
type B. thailandensis to ceftazidime to determine the appropriate
antibiotic pressure for the experiment (see Materials and
Methods). Then, a concentration (5 mg/ml) slightly lower than
three times the wild-type MIC value (1.75 mg/ml based on the E-
TEST, Table S1) was used in the mutant selection process. From a
total of 1610
8 cells on a selection plate, 1 to 10 cells survived to
form visible colonies after 16–20 h incubation, resulting in an
estimated mutation frequency of 10
28 to 10
27.
To investigate the mutation patterns of penA, we sequenced the
gene in resistant B. thailandensis isolates. Intriguingly, all 516
isolates contained a single point mutation in the coding region of
penA (Fig. 1a). To confirm that penA genes with a mutation
(hereafter referred to as penA*s) were responsible for the
ceftazidime-resistance that developed in the mutants, we inacti-
vated the penA* alleles of four randomly selected mutants
containing Cys69Phe, Arg164His, Glu166Lys, or Ala172Thr
substitutions by replacing a region spanning 196 bp in the middle
of the coding region with a tet
r cassette (see Materials and
Methods). All four isolates with inactivated penA* (that are, with
DpenA*s) lost resistance to ceftazidime (MIC #1.75 mg/ml), having
an MIC comparable to the level of the wild-type strain with DpenA
(i.e. E264DP) (Table S1). When a mutant strain with DpenA* was
provided with an intact copy of the penA* in trans, ceftazidime
resistance was restored (Table S1), indicating that penA* was the
factor responsible for ceftazidime resistance.
This penA* selection method conducted in its native (wild-type)
host simply under a high level of antibiotic pressure without an
added mutagen (that is, without an unnaturally elevated mutation
rate, which may result in simultaneous multiple mutations),
enabled us to investigate the functional adaptability of PenA at
the level of single mutations with clear phenotypes. Furthermore, a
short incubation time of 16–20 h under selection, that was the
same as the normal growth time required for the wild-type strain,
ensured that the mutant enzyme sustained a normal growth rate
under high antibiotic pressure. In fact, the same growth rate as
that of the wild-type was observed with all of the mutants (Fig. S1).
Therefore, the set of acquired PenA* enzymes provided informa-
tion about the extent to which changes in amino acid residues are
able to confer high hydrolytic activity against ceftazidime, while
maintaining the necessary integrity of the enzyme. In contrast,
approaches employing artificial mutagenesis often generate
multiple mutations, and in these cases interpreting the contribu-
tion from each mutation is not straightforward [4]. Furthermore,
many such mutations confer only weak hydrolytic activities and/or
cause low enzyme stability, thus making the mutations unsuitable
for selection in natural and/or clinical settings. Although clinically
occurring mutations that evolve in a patient treated with
antibiotics may not have issue of enzyme stability, many of them
do not have clear phenotypes associated with substrate spectrum
expansion and/or only confer weak b-lactam hydrolyzing activity
[4].
Twelve Amino Acid Positions in PenA were Substituted,
each with Distinct Patterns
A total of twelve amino acid positions were repeatedly found
substituted in 516 mutated PenAs (Fig. 1a). Ten of the substituted
amino acids were located in the omega loop, a structural domain
constituting part of the active-site pocket [18]. One of the four
conserved domains [19] in class A b-lactamases,
166EXXLN
170
(numbering following Ambler et al. [17]), is located in the omega-
loop. Notably, all three conserved residues in this domain were
substituted in the set of PenA mutants. The other two substitution
positions were located close to, but not in, two other conserved
domains,
70SXXK
73 and
130SDN
132. However, no substitution
was found near the fourth domain,
234KTG
236 (Fig. 1a).
Each of the twelve positions exhibited one to four different
substitutions out of five to seven substitution choices considering all
possible single nucleotide changes in the codons, totaling twenty
nine substitutions (Fig. 1b). Most (nine of the twelve) positions had
more than two types of substitutions, reflecting that the major
impact of the substitutions is more caused by which residues are
replaced rather than which replaced the original residues.
However, the fact that not all possible residues were found in
the substitutions at each position (Fig. 1b) suggests that there are
specific qualifications required by the substitute residues in each
substitution. In this regard, it is notable that positions Asn170 and
Ala172 exhibited a preference for a molecular weight (MW) range
such that the substitutes were the largest three or four among the
candidates, respectively, regardless of the different R-group
properties (Fig. 1b). Assuming that the MW roughly correlates
with occupying volume by a residue, these substitution patterns
suggest that steric factor may play a role in these substitutions.
Furthermore, the two substitutes for position Cys69 share an
intriguing commonality; both are aromatic residues. In contrast,
three positions Leu162, Thr171, and Asp179 had only one-type of
substitutions (Fig. 1b). At least at positions Leu162 and Asp179
that had a large number of associated isolates (26 and 54,
respectively), the selected substitute residues may be the only
qualified ones. Notably, these residues Leu162 and Asp179 are
present at the either side of the outer boundary of the omega loop,
suggesting that these specific locations may limit diverse substitu-
tions at these positions compared to those inside the omega loop.
Although structural data will be needed to understand the specific
changes made by each substitution, our data formulated by a large
number of mutants clearly unveiled the possible evolutionary paths
of the class A b-lactamase during substrate spectrum expansion.
Each Substitution Exhibited a Distinct MIC Level and
Frequency of Occurrence
The Glu166Lys and Leu169Gln substitutions, which occurred
in the
166EXXLN
170 domain located in the omega loop, resulted
in the highest ceftazidime-hydrolytic activity (Fig. 1a). Interesting-
ly, the Cys69Phe substitution, which occurred outside the omega
loop directly upstream of the essential catalytic Ser70, also resulted
in one of the highest MICs for ceftazidime. That the Glu166Lys
substitution in PenA exhibited high ceftazidime-hydrolyzing
activity (Fig. 1ab and Table S1) is intriguing, because no
substitution at the position Glu166 has been found in clinical
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a key role in b-lactam hydrolysis catalyzing the deacylation step
after the acylation step catalyzed by Ser70 leading to the formation
of an acyl-enzyme intermediate with the b-lactam acylated to the
side chain of Ser70 [19]. This deacylation-deficient PenA* with
Glu166Lys may produce resistance to ceftazidime by a covalent-
trapping mechanism as suggested by a recent study with a
deacylation-deficient mutant TEM with a Glu166Arg substitution
[20].
Among more than two substitutions at some positions, there
were those that better served in terms of the ceftazidime-hydrolytic
activity. Most notably, the three positions in the conserved domain
166EXXLN
170, Glu166, Leu169, and Asn170, showed distinct
MIC levels depending on substitutions, and those with dissimilar
residues appeared to result in high impacts (Fig. 1a). Most notably,
the substitution with highly dissimilar Lys (basic) at position
Glu166 (acidic) showed a much higher level of MIC compared to
the substitutions with nonpolar Gly or Asp, which is also acidic
(Fig. 1ab). At position Leu169 (nonpolar), the substitution with
nonpolar Pro showed the lowest MIC compared to the substitu-
tions with Gln (polar) or Arg (basic). In addition, two of the three
substitutions of Asn170 were with aromatic residues, resulting in
higher MICs than the third substitution with Lys (Fig. 1ab). In
class A b-lactamases, the terminal amide group of Asn170 has
been proposed to play a critical role in the catalysis of b-lactams by
positioning a water molecule in the vicinity of the catalytic Ser70
through a hydrogen-bond network [21]. As the Asn170 mutants
may not have a normal hydrogen bond network, it remains to be
studied how these enzymes maintain their catalytic activity, and
further, how the aromatic substitutes result in high hydrolytic
activity against ceftazidime.
Our data demonstrate that the MIC levels and the relative
frequency in the occurrence of substitutions did not correlate well
with each other (Fig. 1b). This low correlation may be because the
difference in ceftazidime-hydrolyzing activity levels may not be a
critical factor once all of the mutants surpass a threshold-level of
hydrolytic activity required for survival. In fact, our growth
experiment showed the same growth rate for all mutants, which is
comparable to that of the wild-type strain (Fig. S1). It has been
known that the intrinsic nucleotide-level mutational biases present
in bacteria; GRA and CRT transitions have been found to be the
most common non-synonymous mutations [22]. Additionally, a
higher prevalence of the transversion A«T than of ARCo r
TRG has previously been observed in the B. mallei genome [22].
In this regard, it is notable that three of the most frequent
nucleotide substitutions at the twelve positions were indeed the
transitions GRA (Glu166Lys and Asp179Asn) and CRT
(Ala172Val) (Fig. 1b). In addition, at positions Cys69, Arg164,
Ala172, and Asp176, where multiple substitutions occurred, the
transitions GRA and CRT were highly preferred (Fig. 1b).
However, the preference in the transversion A«T was not
observed in the PenA substitutions (Fig. 1b).
Nine of the twenty nine substitutions were found in clinical
isolates of class A b-lactamases (Fig. 1b), and five of these
substitutions (Cys69Tyr [16,23], Arg164His [24], Arg164Ser [24],
Asp179Asn [24], and Leu169Arg [25]) have been verified to cause
substrate spectrum expansion in B. pseudomallei PenA or TEM- or
SHV-type enzymes. Among the twelve substitution positions, only
one (Asp179) had additional substitutions that were found in
TEM- or SHV-type ESBLs but not obtained in our PenA
mutation set (Fig. 1b). As Asp179 could be further substituted,
besides by Asn, by Gln in TEM- and by Gly and Ala in SHV-type
ESBLs (Fig. 1b), it appears that substitution at position 179 is
affected by specific local environment within each b-lactamase.
On the other hand, Met is present instead of Cys at position 69 of
TEM-1 and SHV-1 (Fig. 2). Therefore, derivatives of these
enzymes displayed substitution patterns different from those in
PenA (TEM and SHV Tables summarizing variants in each group
can be found at http://www.lahey.org/Studies/). Position 171 of
TEM-1 and SHV-1 also has a different residue (Glu instead of
Thr) compared to PenA (Fig. 2), however no derivatives of the
enzymes have been identified at this position. Except for positions
69 and 171, all other ten substituted positions in PenA have the
same well-conserved residues as in the other enzymes, including
PenA homologs in B. pseudomallei and B. mallei and the
representative enzymes, TEM-1, SHV-1, and CTX-M-9, that
do not have activity against ceftazidime [26] (Fig. 2). The sequence
conservation at these positions suggests a pivotal role played by
these residues, and this in turn suggests that the expansion of the
substrate spectrum in class A b-lactamases may follow a common
evolutionary trajectory. On the other hand, Pro is present at
position 167 in B. pseudomallei instead of Thr as in B. thailandensis
PenA (Fig. 2), and therefore the Pro167Ser mutation found in
clinical isolates of B. pseudomallei [11] was not obtained in our set of
mutants. Although the effect of this mutation has been confirmed
in B. pseudomallei [23], whether the same affect applies to B.
thailandensis PenA remains to be verified, as the substitute Ser167 is
similar to the original residue Thr167 in B. thailandensis PenA.
The Twelve Amino Acid Positions are Co-localized in the
Enzyme and Appear to cause a Perturbation in the
Omega Loop
To investigate the structural changes in PenA that correlate with
the substrate spectrum expansion to ceftazidime, we conducted
modeling analyses using CTX-M-9 covalently linked to cefoxitin
(PDBID: 1YXM, 58% of amino acid identity to PenA) [27] as a
template. We chose CTX-M-9 for the simulation because of its
high homology to PenA and it does not hydrolyze ceftazidime
similar to wild-type PenA [26]. Simulated 3D models of PenA
showed that the two substituted amino acid positions 69 and 136
co-localized at the active-site pocket area of the enzyme along with
the ten positions in the omega loop (Fig. 3a, b, c).
In our simulations, the size and shape of the binding pocket
did not show significant correlation with each amino acid
substitution. Instead, we observed that the most substitutions of
Arg164 or Asp179 (except Arg164Cys), disrupting the stabilizing
salt bridge between the two residues that clamp the omega loop
structure at both ends [18], resulted in increased distances
between positions 164 and 179 (Fig. 4a). This is consistent with
previous studies that demonstrated that disruptions of the ionic
bond between residues 164 and 179 destabilize the omega loop
Figure 1. Single amino acid substitutions in PenA. a. Map of the twelve positions and twenty nine amino acid substitutions. The PenA protein
is represented by an arrow, on which four conserved domains of sequences and the omega loop are indicated. The twelve positions are denoted by
position numbers (numbering according to Ambler et al. [17]) and the amino acid residues are denoted using the three-letter code. Amino acid
substitutions are shown above the original amino acids. The MIC levels for ceftazidime are shown in the bar graph. b. Substitution patterns in 516
mutated PenA enzymes. For each position, the amino acid residue (AA) of the original and those coded for based on a possible single-nucleotide
mutation are listed with molecular weight (MW) and the number of occurrence (NO). Substitutions previously found in other class A b-lactamases,
that are based on the data from the Lahey Clinic (http://www.lahey.org/Studies/), are denoted by another set of colored symbols.
doi:10.1371/journal.pone.0037585.g001
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higher MIC than the Arg164 mutants (Fig. 1a), also had a
longer 164179 distance in our analysis (Fig. 4a). In addition,
PenA*s with Asn136Asp, Glu166Lys, or Asn170His, also
showed significantly increased distances between positions 164
and 179, suggesting a possibility that the altered local
environment created by some other substitutions may also
affect the interaction between Arg164 and Asp179 (Fig. 4a).
Although each of the amino acid substitutions may have
caused diverse local disturbances, all twenty nine mutations had
the same congruent effect. Specifically, we noted that the space
in the omega loop (calculated as the sum of the distances
between amino acid residues 163 and 174 and between 164 and
173) increased in all PenA*s, including those with substitutions
outside the omega loop, compared to the wild-type PenA
(Fig. 4b). We postulate that increased space in the omega loop
may accompany increased flexibility of the loop in the mutant
enzymes. Then, this flexibility would in turn relieve steric
hindrance between the omega loop and the bulky 7b-side chain
of ceftazidime, thereby increasing accessibility of ceftazidime to
the binding pocket [30,31].
PenA*s have Altered Activities for Hydrolyzing Various b-
lactam Antibiotics
Our data comparing the MICs of the wild-type strain E264 and
the various mutant strains showed that PenA is responsible for the
intrinsic moderate insensitivity of the wild-type strain E264 to
various classes of b-lactam antibiotics, including amoxicillin,
ceftriaxone and cefotaxime (a 3
rd-generation cephalosporin), and
cefepime (a 4
th-generation cephalosporin) (Table S1).
To investigate the extent to which the structural changes in the
PenA*s that were adjusted to ceftazidime affect the enzyme
activity towards other b-lactam antibiotics, we measured the MICs
for selected b-lactam antibiotics. These antibiotics included the
four that the wild-type enzyme was able to hydrolyze and a
carbapenem antibiotic (meropenem) and a b-lactamase inhibitor
(clavulanic acid with amoxicillin). All PenA*s generally exhibited
decreased levels of resistance to the original substrates as observed
in many mutants of the class A b-lactamase that acquired activity
to 3
rd generation cephalosporins [32] (Table S1). The hydrolytic
activities of all PenA*s against amoxicillin (MIC range: 3 , 24 mg/
ml) were effectively inhibited by clavulanic acid. In addition,
resistance to meropenem was not observed in the wild-type or the
mutants (Table S1).
A Second-phase Selection did Not Result in a Mutation in
the Coding Region but Rather in the Promoter of penA
To investigate whether PenA*s accumulate more mutations
under an elevated level of ceftazidime, we conducted a second-
level selection with three randomly chosen PenA mutants,
containing Cys69Phe, Glu166Lys, or Asp179Asn (see Materials
and Methods). The selection process did not result in any
additional changes to the coding region, but the same single point
mutation, GRA in the region upstream of penA, was observed in
seven of the eleven second-phase mutants derived from all three
mutants (Fig. 5a). Intriguingly, this mutation also has been
identified in a clinical isolate of B. pseudomallei, and was noted
conferring CAZ resistance [16]. The GRA point mutation lies in
the putative -10 sequence 59-TACGCT-39, changing it to 59-
TACACT-39, which is closer to the consensus sequence for the -10
sequence in E. coli,5 9-TATAAT-39. One of these mutants,
E166K1-F1, derived from the mutant E166K1 with Gln166Lys,
was further investigated. This mutant showed a significant increase
in hydrolytic activity against ceftazidime compared to the parental
strain E166K1 (Fig. 5b). The double mutant penA* fragment from
E166K1-F1 carried by pRK415K conferred an approximately
three-fold increase in MIC value compared to a similar clone with
a fragment from E166K1 in the E264(DpenA) background (Fig. 5b).
Figure 2. Sequence conservation of the 12 substituted positions in PenA among class A b-lactamases. PenA proteins from B.
thailandensis (Bt), B. pseudomallei (Bp), and B. mallei (Bm) and representatives of the three largest families of class A b-lactamases, TEM-1, SHV-1, and
CTX-M-9, are aligned. The twelve positions with changes in Bt PenA* are denoted in shades of gray. Positions 69 and 167 have residues in other b-
lactamases that differ from those of B. thailandensis PenA, which are denoted with blue and red arrowheads, respectively. Three of the four conserved
domains in class A b-lactamases,
70SXXK
73,
130SDN
132, and
166EXXLN
170, are denoted by boxes on the Bt PenA sequence.
doi:10.1371/journal.pone.0037585.g002
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37585Figure 3. Simulated structure of wild-type PenA. The twelve amino acid positions that are targets for substitution are highlighted. a. Clustering
of the twelve amino acid residues in PenA. The front, side, and back views of the simulated structure are shown. Each amino acid residue is color-
coded for distinction. The predicted binding site, identified using CASTp [48] by comparing PenA with the binding site of CTX-M-9 interacting with
cefoxitin, is denoted with a red closed circular line. b. A closer look at the twelve-residue cluster. The front, side, and back views of the twelve-
residues, each numbered from 1 to 12, are shown. Red boxes denote residues Cys69 (1) and Asn136 (2), which are distinct from the rest of the
residues because they are not part of the omega loop. C. The omega loop structure with ten substituted residues denoted by red solid circles and the
other residues by unfilled circles.
doi:10.1371/journal.pone.0037585.g003
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penA* expression, we compared the transcriptome profiles of
E166K1-F1 and E166K1 obtained before and 1 h after ceftazi-
dime challenge (see Materials and Methods). Intriguingly, the
basal level expression of penA* was approximately four-fold higher
in E166K1-F1 than in E166K1, but there was no further induction
in response to the addition of ceftazidime (Fig. 5c). In contrast, no
other genes were differentially expressed as highly as penA*i n
E166K1-F1 compared with E166K1 (data not shown). In addition
to the promoter mutations, there were a smaller number of other
isolates (four of the eleven) for which we could not find a mutation
in the promoter or in the coding region of penA*. This finding
suggests that there may be an additional determinant that
contributes to resistance to ceftazidime in Burkholderia thailandensis.
Figure 4. Altered distances in the omega loop in PenA*. The measured distances are denoted A, B, and C in the simulated 3D omega loop
structure. a. Alteration in the distance between positions 164 and 179. The distance between positions 164 and 179, where the ionic bond is present
(at least in the wild type), of each of the PenA*s is compared to that of the wild-type in a bar graph. b. Altered internal space in the omega loop in
PenA*s. The sum of the distances between positions 164–173 and 163–174 in the omega loop is compared to that of the wild-type in the bar graph.
doi:10.1371/journal.pone.0037585.g004
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In our mutant selection, a large proportion of the mutations in
the bacterium were expected to occur in penA; however, the finding
that all 516 ceftazidime-resistant isolates that we collected had a
mutation in this gene was intriguing. This result strongly suggests
that the class A b-lactamase PenA is a predominant determinant
for the development of ceftazidime resistance in B. thailandensis and
perhaps more widely in Burkholderia spp. This notion is supported
by the fact that most of the validated mutations associated with
ceftazidime resistance in B. pseudomallei and B. cepacia have to date
been located in penA homologs [9,10,11,23,33]. In the second-
phase mutant selection with an increased antibiotic challenge, we
obtained mutations that were not associated with penA but were
present elsewhere in the genome, demonstrating the presence of
other genetic determinants. In clinical Pseudomonas aeruginosa
isolates, which often lack class A b-lactamase genes, the
development of ceftazidime-resistance could be a result of various
mechanisms with multiple determinants [34]. There certainly is a
possibility that homologs of these P. aeruginosa genes, including
those coding for class B and D b-lactamases, efflux pumps, and
porins, may have mutations associated with ceftazidime resistance.
The levels of ceftazidime resistance in clinical B. pseudomallei
isolates [35,36] and in Bcc [37,38] have been determined to be
low. However, the continued use of ceftazidime in clinical settings
suggests the potential for the increased emergence of ceftazidime
resistance in these bacterial groups. Furthermore, as SHV and
Figure 5. Mutations from the second-round selection with an increased ceftazidime level. a. The GRA point mutation found in the
putative promoter region of penA. Nucleotide sequences of the wild-type (E264) and the mutant (E166K1-F1) with a point mutation in the putative
promoter of penA (E166K1-F1) of B. thailandensis (Bt) are shown and are aligned with multiple sequences from B. pseudomallei (Bp) and B. mallei (Bm)
strains. The point mutation is denoted with a label and highlighted. The putative -10 and -35 regions are denoted in shades of red and blue,
respectively, and putative start codons (ATG) are denoted with red boxes. b. Ceftazidime-hydrolyzing activities of the promoter mutant. The
ceftazidime (CAZ) MIC values of a promoter mutant (E166K1-F1) and its parental strain (E166K1) are compared in the bar graph. Vector-carried penA*
fragments from E166K1-F1 and E166K1 are also compared in the background of E264(DpenA). c. Comparison of the transcription levels of the
promoter mutant (E166K1-F1) and its parental strain (E166K1). The relative expression levels measured by microarrays are shown in the graph.
doi:10.1371/journal.pone.0037585.g005
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somal b-lactamases of Klebsiella pneumoniae [39] and Kluyvera species
[6], respectively, Burkholderia penA also has the potential to cause a
global impact if it becomes mobile.
Substitutions in the omega loop, especially at positions 164, 166,
and 179, have been reported to seriously affect the stability of
TEM b-lactamases [20,32]. However, the Met182Thr substitution
was shown to restore the stability of these enzymes [20,32]. As
PenA*s with a perturbation in the omega loop produced high
ceftazidime-hydrolyzing activity without obvious growth retarda-
tion of the host bacteria (Fig. S1), it is intriguing to note that PenA
contains a Thr residue at position 182 (Fig. 2). However, it remains
to be investigated if the Thr182 in PenA contributes as a global
stabilizer for the vast array of substitutions we obtained in the
active site area.
Mapping twelve positions and their twenty nine single amino
acid substitutions in a class A b-lactamase capable of altering the
substrate spectrum of the enzyme is unprecedented. Notably, only
seven of these twelve positions and nine of the twenty nine
mutations have been reported in clinical isolates of TEM- or SHV-
type b-lactamases, or in the PenA homologs of other Burkholderia
spp., and not all of these have been reported with confirmation in
their effects on the substrate spectrum expansion. These data have
substantial value, representing a comprehensive repertoire of
enzyme adaptability that can occur in clinical settings. These
mapped amino acid positions and substitutions with clear
ceftazidime resistance phenotypes provide an invaluable resource
for the development of preventive strategies and treatments against
not only ceftazidime resistance in pathogenic Burkholderia species
but also in ESBLs in general that share functional mechanisms in
their evolution against new drugs using common features of
conserved residues.
Materials and Methods
Bacterial Cultures
All Escherichia coli strains were grown in Luria Bertani (LB)
media, and all B. thailandensis strains were grown in LB or AB
minimal media containing 0.25% glucose (ABG) [40] at 37uC.
The concentrations of antibiotics used for E. coli were as follows:
tetracycline, 10 mg/ml; kanamycin, 50 mg/ml; and ampicillin,
100 mg/ml. For B. thailandensis, the concentrations of tetracycline
and kanamycin used were 50 mg/ml and 250 mg/ml, respectively.
Determination of the MIC (Minimal Inhibitory
Concentration) Values
The MIC values were measured by the E-test [41], following the
manufacturer’s instructions (AB Biodisk, Solna, Sweden). Briefly,
each strain was grown on Mu ¨ller-Hinton agar plates at 37uC for 2
days. For the strains harboring pRK415K-derived plasmids,
Mu ¨ller-Hinton agar supplemented with kanamycin (250 g/ml)
was used. Single colonies from the plates were suspended in 1 ml
PBS until the turbidity reached 0.5 MacFarland standard. Using
sterile cotton swabs, cell suspensions were spread on the Mu ¨ller-
Hinton agar plates, the E-test strips were placed, and the plates
were incubated at 37uC for 16,18 h. The lowest concentrations
at the E-test strips where no visible growths were observed were
recorded as the MICs. Average values were calculated from
triplicate experiments.
The agar dilution method was conducted as described by
Wiegand et al. [42], except that LB agar was used instead of
Mueller Hinton agar. Briefly, a single colony of each strain grown
on ABG minimal medium agar was used to inoculate 2 ml of LB
broth, and the culture was incubated overnight with shaking
(250 rpm) at 37uC. The overnight cultures were serially diluted
with fresh LB and dispensed into the wells of a 96-well microtiter
plate. Using a multi-channel micropipette, 1 ml of the diluted
bacterial suspensions was placed on each LB agar plate containing
0.5 to 8 mg/ml of ceftazidime and incubated at 37uC for 16 to
20 h. The lowest concentration of antibiotic such that there was no
visible bacterial growth was observed in the spot containing
approximately 10
4 CFU (colony forming unit), which was
recorded as the MIC. The number of CFUs in serially diluted
bacterial suspensions was determined by spreading 100 ml of the
appropriately diluted bacterial suspensions on LB agar plates,
followed by incubating the plates for 24 h at 37uC, and counting
the viable cells. The average values were calculated from triplicate
experiments.
Isolation of Mutants Resistant to Ceftazidime
A single colony of the wild-type B. thailandensis strain E264 was
grown overnight in 2 ml of LB broth at 37uC with shaking
(250 rpm). The overnight culture was pelleted by centrifugation
(2,600 X g) for 5 min at 4uC, and the cells were resuspended in
fresh LB broth to approximately 10
9 CFU/ml. Cell suspensions
(100 ml) were spread on LB agar plates containing 5 mg/ml
(slightly lower than three times the wild-type MIC) ceftazidime,
which were subsequently incubated for 48 h at 37uC until
ceftazidime resistant mutants formed visible colonies. We picked
two to three colonies from each selection plate to collect up to 516
isolates for this study. A second-round selection was conducted
with an elevated concentration of ceftazidime (96 mg/ml) with
selected ceftazidime-resistant mutants.
Localization of the Mutations in penA
To map the mutations in penA (BTH_II1450 in the strain E264
genome), we first set out to sequence the gene. Genomic DNA of
each ceftazidime-resistant mutant was purified using a Wizard
Genomic DNA Purification Kit (Promega, Madison, USA) and
was used as the template for PCR amplification of penA and short
flanking regions for a 1,386 bp amplicon (271 bp upstream from
the start codon of the gene to 230 bp downstream of the stop
codon). PCR reactions were conducted in a 50 ml reaction mixture
containing 2.5 U of HotStar HiFidelity polymerase (Qiagen,
Hilden, Germany), 50 pmol of the primers penA-F (59-
CGTCAATCCGATGCAGTACC-39) and penA-R (59-
GCCGTTATCGCACCTTTATC-39), 100 ng template DNA,
10 ml of 5X Q solution, and 10 ml of 5 X HotStar HiFidelity
buffer. The reaction consisted of the following three steps: initial
enzyme activating step (95uC for 5 min), amplification step (35
cycles of 94uC for 15 sec, 61uC for 1 min, and 72uC for 1.4 min),
and final extension step (72uC for 10 min). Gel-purified 1.4 kb
PCR products were sequenced using a 3730XL DNA analyzer
(Applied Biosystems, Foster City, CA, USA) in both directions
using primers penA-F and penA-R.
Construction of penA-null Mutants
The wild-type and mutated penA genes were disrupted as
follows. First, the wild-type penA was PCR-amplified, using the
primer pairs penA-KF (59-ATATATGGTACCCGTCAATCC-
GATGCAGTACC-39) and penA-KR (59-ATATATGG-
TACCGCCGTTATCGCACCTTTATC-39), containing a KpnI
recognition site (underlined) at the end. Then the 1.4 kb PCR
product was digested with KpnI and ligated into pUC19, which
was digested with the same enzyme. The resulting plasmid was
double-digested with XhoI and PflFI to remove an internal region
(position 124 bp to 319 bp) of penA, which is 885 bp long, blunt
ended with T4 DNA polymerase (NEB, Ipswich, MA, USA), and
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r) cassette by
ligation. The tet
r cassette was previously amplified from pRK415K
[43], using HotStar HiFidelity polymerase (Qiagen, Hilden,
Germany) and primers tetR-F (59-ATATATCTCGAGGT-
GAGGCTTGGACGCTAGG-39) and tetR-R (59-
ATATTTCTCGAGCTTGGATCAGACGCTGAGTG-39), con-
taining a XhoI recognition site (underlined), XhoI-digested, and
blunt-ended. The construct was transferred into B. thailandensis
strains employing a modified method of natural transformation
[44]. Briefly, 3 ml of a defined medium (DM) prepared as
described by Thongdee et al. [44] was inoculated with a single
colony freshly grown on LB agar and was incubated overnight
with shaking at 250 rpm at 37uC. The overnight culture of 200 ml
was diluted with 10 ml of fresh preheated DM and the culture was
grown with shaking (250 rpm) at 37uCt oa nO D 600 of
approximately 0.5. The culture was then concentrated 20-fold in
500 ml fresh DM and 50 ml aliquots of the concentrated cells were
mixed with 0.5 mg of plasmid DNA. The mixture was incubated
for 30 min on ice and 2 ml DM preheated to 37uC was added and
the mixture was incubated overnight at 250 rpm at 37uC. After
washing the culture with 1 ml of fresh DM and resuspending the
pellet in 250 ml of fresh DM, 100 ml of the cell suspension was
plated on ABG medium containing 50 mg/ml tetracycline and
incubated at 37uC for 48 hrs to select for tet
r cassette-containing
constructs. An obtained penA null mutant was verified by PCR
using a primer pair penA_LF (59-AACAGATCGCCGAGATGG-
39) and penA_LR (59-GCGAACGTTGCCCGATAC-39) that
hybridize to the genomic regions outside the DNA sequence used
for mutant construction.
Complementation of the penA Mutations
KpnI-treated PCR products of penA* (penA with a single
nucleotide mutation), which was amplified using the primers
penA-KF and penA-KR as described above, was ligated with
KpnI-treated pRK415K. This plasmid was transferred into the E.
coli strain S17-1 [45] by using a conventional transformation
method [46]. The transformed S17-1 strain was conjugated with a
B. thailandensis penA-null mutant on ABG agar plates containing
250 mg/ml kanamycin, and the plates were incubated at 37uC for
2 days to select for transconjugants. A successful conjugation was
confirmed by purifying the plasmid from transconjugants and
examining the characteristic restriction patterns of the plasmid.
Modeling Analysis
Because the structure of PenA is not known, the structures (for
both mutants and wild-type) were predicted by homology
modeling using CTX-M-9 (PDBID: 1YXM, 58% of identity)
[27] as a template with SYBYL-X (Tripos Inc., St. Louis, MO,
USA). With the predicted structures, molecular dynamic simula-
tions were conducted using OpenMM Zephyr 2.0.3 [47] for
500 ps (0.002 ps/step) at 303.15 K with the Amber03 force field
to release any structural constraints originating from the template.
Then, energy minimization was performed using SYBYL -X
(Tripos Inc., St. Louis, MO, USA) with a Tripos force field until
the energy gradient reached 0.001 kcal/(molNA).
Gene Expression Study
Gene expression was assayed using microarray technology. The
bacterial culture was incubated in LB media until the OD600
reached 0.5, then 2 ml of the culture was taken and mixed with
4 ml of RNAprotect bacteria reagent (Qiagen, Hilden, Germany)
to prevent alterations in the transcriptome. For cultures that were
induced by ceftazidime, a sub-MIC level of ceftazidime (24 mg/ml)
was added, the samples were withdrawn after 1 hr, and were
immediately mixed with two volumes of RNAprotect bacteria
reagent. Total RNA isolation and labeling with Cy3 and Cy5
fluorescence dyes were conducted following PFGRC SOP (http://
pfgrc.jcvi.org/index.php/microarray/protocols.html).
Labeled samples were hybridized to the B. thailandensis whole
genome microarray (MYcroarray, Ann arbor, MN, USA) in a
hybridization chamber in a 42uC water bath for 16 to 20 hrs.
Microarray slides were washed twice with 1 x SSPE for 3 min and
then with 0.25 x SSPE for 30 sec, and were dried immediately by
spinning in a micro-slide centrifuge for 1 min. Hybridized slides
were scanned using a GenePix 4000B microarray scanner
(Molecular Devices, LLC, Sunnyvale, CA, USA). The scanned
images were analyzed using TIGR SPOTFINDER (http://www.
tm4.org) to obtain relative transcript levels. LOWESS (locally
weighted scatterplot smoothing) normalization of data was
executed using the software tool MIDAS (http://www.tm4.org).
The resulting data were visualized and further explored by using
TMEV (http://www.jcvi.org/cms/research/software).
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